Concord Biotech has informed the National Stock Exchange (NSE) that it has completed the acquisition of 100% equity in Celliimune Biotech Private Limited for Rs 66 lakh in cash, further sharpening its focus on advanced cancer therapeutics.

The disclosure was made through a regulatory filing dated April 2, 2026, under Regulation 30 of SEBI’s listing norms. 

In its statement to the NSE, Concord said the acquisition is aimed at advancing pioneering research in DNA engineering for cancer therapeutics and developing innovative alternatives to conventional chemotherapy. The company added that the acquisition is expected to help innovate new therapies for the treatment of cancer, signaling a strategic move into the rapidly evolving cell and gene therapy space. 

Celliimune, incorporated in January 2025, specializes in the discovery, development, and commercialization of novel cell and gene therapy solutions. With the transaction now complete, the company has become a wholly owned subsidiary of Concord Biotech. The filing also noted that Celliimune currently has nil turnover, indicating that the acquisition is focused on long-term scientific capability rather than immediate commercial returns. 

Concord further stated in the NSE filing that the deal qualifies as a related party transaction, but was executed on an arm’s-length basis. The acquisition underscores the company’s broader ambition to expand beyond its core strengths and build a differentiated presence in precision oncology and next-generation biopharmaceutical innovation.